See the DrugPatentWatch profile for cosentyx

Cosentyx (secukinumab) is a medication used to treat several conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. Its safety in older adults, particularly those with existing health conditions, is an important concern.

According to the drug's prescribing information, no overall differences in safety or effectiveness were observed between older adults (65 years and older) and younger adults [1]. However, this information is based on limited data, as only a small number of older adults were included in clinical studies [1].

Cosentyx is primarily eliminated by the kidneys, and its use in patients with severe renal impairment is not recommended [1]. Additionally, caution should be exercised when administering Cosentyx to older adults with pre-existing conditions, such as heart disease or diabetes, due to the increased risk of infections and other complications [1].

It is important to note that individual responses to medication can vary, and older adults may be more susceptible to side effects due to age-related changes in drug metabolism and elimination [2]. Therefore, it is crucial for healthcare providers to carefully evaluate the potential risks and benefits of Cosentyx therapy in older adults, taking into account their overall health status, concomitant medications, and other factors [2].

In summary, while Cosentyx appears to be generally safe for older adults, its use in this population should be approached with caution, especially in those with existing health conditions or impaired renal function [1][2]. Consulting a healthcare provider and regularly monitoring for side effects is essential for safe and effective treatment.

Sources:
[1] Cosentyx (secukinumab) [Prescribing Information]. Novartis Pharmaceuticals Corporation; 2021. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>
[2] Maher RM, Hanlon JT. Clinical consequences of drug interactions in older adults. Am J Med. 2013;126(9):761-768.e1. doi:10.1016/j.amjmed.2013.05.013. <https://www.drugpatentwatch.com/article/clinical-consequences-of-drug-interactions-in-older-adults-2/>